GlassScriptPhysician profile
Thomas Ryan Gallaher
NPI 1235450453
$155,300.06
in general payments reported to CMS, 2019-2025
39 companies · $8,325 in 2025
The $8,325 reported for 2025 was more than what 92% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $17K · 2021: $17K · 2022: $9,072 · 2023: $21K · 2024: $18K · 2025: $8,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Travel and Lodging: $4,920 · Consulting Fee: $4,226 · Food and Beverage: $2,999 · Education: $92.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,238.75 |
| Travel and Lodging | $4,919.65 |
| Consulting Fee | $4,226.00 |
| Food and Beverage | $2,998.77 |
| Education | $92.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $101,107.37 | 2019-2025 | Epclusa, Veklury |
| Abbvie INC. | $25,108.83 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $8,966.73 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Allergan, INC. | $7,784.10 | 2019-2021 | |
| Insmed, INC. | $7,248.29 | 2019-2025 | Arikayce |
| Astellas Pharma US INC | $1,930.88 | 2019-2024 | Cresemba |
| Melinta Therapeutics, LLC | $807.71 | 2019-2025 | Rezzayo, Orbactiv, Kimyrsa |
| Viiv Healthcare Company | $636.90 | 2019-2024 | Dovato, Cabenuva, Rukobia |
| Novo Nordisk INC | $246.11 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $211.79 | 2019-2024 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.46 | 2019-2022 | |
| Tetraphase Pharmaceuticals, INC. | $127.27 | 2019 | |
| Shionogi INC | $116.66 | 2023 | Fetroja |
| Lilly USA, LLC | $106.06 | 2021-2024 | Mounjaro, Zepbound |
| Janssen Products, LP | $99.95 | 2019 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gallaher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.